ABSTRACT
Forty-one patients with inoperable non-small cell lung cancer were randomized to receive irradiation therapy 45 Gy in ten fractions over eight weeks, plus either placebo or misonidazole 1.2 g/m2 orally on treatment day. The irradiated area was the primary tumour. Twenty-one patients received misonidazole and 20 received placebo. Minimal observation time for the study was 36 months. No clear difference was observed in the pattern of relapse between the groups. 43% of the patients in the misonidazole group attained a complete response (CR) or partial response (PR) as compared with 65% in the placebo group. Median survival time was twelve months in the misonidazole group and 14 months in the placebo group.
Subject(s)
Carcinoma, Non-Small-Cell Lung/radiotherapy , Lung Neoplasms/radiotherapy , Misonidazole/therapeutic use , Radiation-Sensitizing Agents/therapeutic use , Aged , Carcinoma, Non-Small-Cell Lung/drug therapy , Clinical Trials as Topic , Combined Modality Therapy , Double-Blind Method , Female , Humans , Lung Neoplasms/drug therapy , Male , Middle Aged , Prognosis , Random AllocationABSTRACT
Brodimoprim and doxycycline monotherapies were compared in the treatment of acute respiratory tract infections in a randomized double-blind trial. The brodimoprim dose was 400 mg as a single loading dose followed by 200 mg for 10 days at bedtime. The corresponding doses of doxycycline were 200 and 100 mg respectively. Both treatment groups consisted of 30 patients. In the brodimoprim group, 23 patients recovered completely, five improved and two did not respond. In the doxycycline group, 26 patients recovered completely, three improved and one was considered a failure. Only one patient in the brodimoprim group had moderate diarrhoea.
Subject(s)
Doxycycline/therapeutic use , Respiratory Tract Infections/drug therapy , Trimethoprim/analogs & derivatives , Adolescent , Adult , Clinical Trials as Topic , Double-Blind Method , Doxycycline/administration & dosage , Drug Tolerance , Humans , Random Allocation , Trimethoprim/administration & dosage , Trimethoprim/therapeutic useABSTRACT
The efficacy of midazolam vs lorazepam and placebo was studied in 60 patients in a comparative, double-blind study. Midazolam 15 mg and lorazepam 2.5 mg were given orally in a single dose the night before operation. Sleep latency was shortest on midazolam but the mean duration of sleep longest on lorazepam. Four patients on lorazepam complained of headache and one reported tinnitus. Three patients receiving midazolam complained of headache. Headache was observed also in one patient given placebo and another experienced tachycardia. Midazolam administered the night before surgery is a preferable hypnotic for transient insomnia caused by preoperative anxiety.
Subject(s)
Anti-Anxiety Agents , Benzodiazepines , Lorazepam , Preanesthetic Medication , Adult , Anti-Anxiety Agents/adverse effects , Benzodiazepines/adverse effects , Clinical Trials as Topic , Double-Blind Method , Female , Humans , Lorazepam/adverse effects , Male , Midazolam , Middle Aged , Random Allocation , Sleep/drug effectsABSTRACT
The antipyretic activity of tenoxicam was compared with that of paracetamol. Thirty-eight inpatients aged between 6 months and 16 years, with a rectal temperature of above 38.5 degrees C, were divided into four groups. Patients received tenoxicam (0.3, 0.6 or 1.2 mg/kg) or paracetamol (10 mg/kg) in a single oral dose. Rectal temperatures were recorded before admission, 30 min and 1, 2, 3, 4, 5 and 6 h after administration of the drug. The fall in temperature was significant in the paracetamol group and in one tenoxicam group with a dose of 1.2 mg/kg. Doses of 0.3 and 0.6 mg/kg of tenoxicam had only a slight effect. It was concluded that tenoxicam has a slight antipyretic effect, but is not an alternative to paracetamol as an antipyretic drug in the treatment of fever in children.
Subject(s)
Acetaminophen/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Fever/drug therapy , Piroxicam/analogs & derivatives , Thiazines/therapeutic use , Adolescent , Child , Child, Preschool , Clinical Trials as Topic , Female , Humans , Infant , MaleABSTRACT
Concentrations of carprofen in the serum and the synovial fluid were determined in 13 patients with classical or confirmed rheumatoid arthritis. Four hours after the oral administration of 100 mg of carprofen, as one capsule, concentrations in the synovial fluid were found to be between 3.5 micrograms/ml and 9.7 micrograms/ml, with a mean value (+/- SD) of 6.2 +/- 1.4 micrograms/ml, and concentrations in the serum were between 4.7 micrograms/ml and 14.8 micrograms/ml, with a mean value of 9.8 +/- 2.9 micrograms/ml. The carprofen concentrations in synovial fluid varied from 36.3 to 103.0% of those in serum, with a mean value of 65.0 +/- 14.4%. There is a highly significant correlation between carprofen concentrations in the serum and the synovial fluid.
Subject(s)
Anti-Inflammatory Agents/analysis , Arthritis, Rheumatoid/metabolism , Carbazoles/analysis , Synovial Fluid/analysis , Anti-Inflammatory Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Carbazoles/therapeutic use , HumansABSTRACT
The efficacy and clinical effects of flunitrazepam (1 mg) and nitrazepam (5 mg) as somnifacients were studied in 37 psychogeriatric inpatients. Each drug was administered in a double-blind manner to randomized groups of patients for 14 nights. Compared with placebo, both benzodiazepines proved to be effective in inducing and maintaining sleep. Although both drugs were well tolerated, insomnia resulted when each was withdrawn.
